Deficiencies Found At Ranbaxy’s Toansa Plant In Punjab
Advertisement
Advertisement
European regulators completed their assessment of manufacturing violations at Toansa plant in Punjab. The regulators found some deficiencies, but it was ascertained that they posed no serious risk to public health.The regulators said they were satisfied by the corrective measures taken by the company. They also restored the ‘good manufacturing practices’ certificate that was suspended in January 2014.
The
The European regulators sent their inspectors from Germany, Ireland and the UK, who were joined by inspectors from Switzerland and Australia, the European Medicines Agency (EMA) said in a statement.
Advertisement
“The inspection team concluded that there was no evidence that medicines in the EU market, which have an active pharmaceutical ingredient manufactured in Toansa, were of unacceptable quality or posed any risk to the health of patients taking them,” said EMA. “This conclusion was supported by tests of samples of these medicines, all of which met the correct quality specifications.”
According to the agency, “European regulatory authorities have identified the need to keep the Toansa site under close supervision and this will be done in collaboration with India and other regulatory authorities around the globe.”
Ranbaxy did not immediately comment on the development. The FDA, however, has said it will not lift its ban on Ranbaxy until it is satisfied with the products.
Advertisement
- Should you be worried about the potential side-effects of the Covishield vaccine?
- India T20 World Cup squad: KulCha back on menu, KL Rahul dropped
- Sales of homes priced over ₹4 crore rise 10% in Jan-Mar in top 7 cities: CBRE
- Gold prices fluctuate as geopolitical tensions ease; US Fed meeting, payroll data to affect prices this week
- Best beaches to visit in Goa in 2024
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market